At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.
At the 2024 Lymphoma, Leukemia &...